Resonant’s platform allows for the simultaneous discovery of novel targets and high affinity, functional antibodies with unprecedented speed. Using novel insights into the tumor microenvironment and the immune system, our platform identifies targets and therapeutic candidates for any patient derived tumor tissue or cell line, including cancer stem cells. The platform is extensible to other microenvironment regulated disease.
We have created a pipeline of candidates with potent, direct anti-tumor activity, initially in breast and ovarian cancers. Our antibodies are expected to work as a monotherapy or in synergistic combination with emerging immunotherapies.